Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duke’s Califf Bows Out Of FDA Search; Quest Moves To Baltimore, New York

This article was originally published in The Pink Sheet Daily

Executive Summary

Baltimore Health Commissioner Sharfstein would appear to be the favorite, but former New York City health official Hamburg is said to be on the shortlist.

You may also be interested in...



FDA Chief Scientist Ostroff Named Acting Head With Hamburg On Way Out

Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and praise from industry groups. Chief Scientist Stephen Ostroff has been named acting head, and some speculate that Robert Califf, newly appointed deputy commissioner for medical products and tobacco, is in line to succeed Hamburg on a permanent basis.

FDA Lands Califf As Top Deputy, Potential Next Commissioner

Renowned cardiologist and clinical trial researcher Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. Califf is director of Duke University’s Translational Medicine Institute and vice chancellor for Clinical and Translational Research.

FDA Lands Califf As Top Deputy, Potential Next Commissioner

Renowned cardiologist and clinical trial researcher Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. Califf is director of Duke University’s Translational Medicine Institute and vice chancellor for Clinical and Translational Research.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel